Date: Jul 29, 2013 Source: Company Data (
click here to go to the source)
Rib-X Pharmaceuticals, Inc. and Sanofi today announced the conclusion of their collaboration on the research and development of RX-04.
The RX-04 research program is investigating a potentially novel class of antibiotics to combat both Gram-positive and Gram-negative resistant bacteria. The program is targeting a unique site within the bacterial ribosome, an internal cell component critical to antibacterial activity.
With the conclusion of the collaboration, Rib-X Pharmaceuticals retains all rights to the discovery and global commercialization of RX-04.
"Rib-X Pharmaceuticals is working toward a near-term Investigational New Drug Application to begin human clinical trials on RX-04," says Mary T. Szela, Chief Executive Officer of Rib-X Pharmaceuticals. "We are committed to realizing the full potential of this important science by bringing a needed novel class of antibiotics to market."
The companies cite strategic reasons for ending the collaboration.
About Rib-X:
Rib-X Pharmaceuticals is focused on the discovery, development and commercialization of novel antibiotics. Rib-X Pharmaceuticals' investigational fluroquinolone, delafloxacin, is in Phase 3 development for ABSSSI (acute bacterial skin and skin structure infections). Based on Nobel Prize-winning science, Rib-X Pharmaceuticals' research platform includes RX-04, a new class of antibiotics with potential to treat life-threatening drug-resistant infections, including ESKAPE pathogens. Rib-X is privately held and backed by Vatera Healthcare Partners and Warburg Pincus, among others. For more information, please visit www.rib-x.com.
